About 330 results
MOR208 targeting the CD19 B cell antigen is promising treatment of advanced lymphomas
Precision cancer medicines expand options for treatment of GIST
LOXO-305 induced responses in CLL and Mantle Cell Lymphoma including patients with BTK and BCL2 resistance
Clinical trial results for novel Myelofibrosis treatments were updated at the 2019 Amer Soc Hematology meeting.
Initial clinical results for REGN 5458 Bispecific Antibody appear promising for treatment of advanced myeloma.
Tazemetostat - a novel precision cancer medicine - promising for Sarcoma.
Anit-angiogenic - immunotherapy combination represents new treatment option for recurrent ovarian cancer.
Melflufen demonstrates long term survival benefit in patients with advanced Multiple Myeloma.
CC-932269 is a bispecific antibody being developed for Multiple Myeloma that appears to have anti-myeloma activity.
Triplet immunotherapy - BL-8040 combination shows promising responses in metastatic pancreatic cancer.